This is a clinical-stage biotechnology company developing immuno-oncology therapies. It is focussed on developing its self-delivering ribonucleic acid interface (RNAi) INTASYL therapeutic platform to precisely target specific proteins that reduce the body’s ability to fight cancer without the need for specialized formulations or drug delivery systems.